Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Indiana
Clinical trial register · United States · industry-sponsored

Clinical Trials in Indiana, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 113 Florida 110 Massachusetts 66 Georgia 63 Illinois 62
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company49 AstraZeneca41 AbbVie41 Janssen Research & Development, LLC39 Novartis Pharmaceuticals31 Clear sponsor filter
State
California113 Florida110 Massachusetts66 Georgia63 Illinois62
All 47 states
Target enrolment
to

Trials with a site in Indiana

31 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924Cutaneous Lichen Planus
DrugGIA632
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-10
Recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07700056Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
710
Arkansas, California, Florida, Illinois, Indiana, Nebraska, New York, North Carolina
2026-07-10
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Connecticut, Florida, Georgia, Indiana, Maryland, New Jersey, New York, Ohio
2026-05-27
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
DrugGIA632
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Indiana, Michigan, Nebraska, Nevada, New York
2026-03-09
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
DrugsLuxdegalutamide·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Active, closed
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
246
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Active, closed
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Hypertension
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Active, closed
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Active, closed
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Active, closed
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298Prostatic Neoplasm
DrugsARPI·Pylarify·Illuccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
49
Colorado, Georgia, Indiana, Iowa, Nebraska, Oregon, Pennsylvania, Texas
2024-01-03
Recruiting
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 4
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-08-14
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Minnesota
2023-07-06
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
436
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-03-02
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
226
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts
2023-02-03
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
610
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195Metastatic Breast Cancer
DrugsGoserelin·Tamoxifen·Anastrozole·Ribociclib
Novartis Pharmaceuticals
Phase 4
134
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-07-07
Active, closed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537Age-Related Macular Degeneration
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Florida, Indiana, Louisiana, Maryland, Massachusetts, New Jersey
2022-02-17
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas
2021-12-13
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Colorado, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts, New Jersey
2021-07-28
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky
2021-04-09
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
California, Colorado, Florida, Illinois, Indiana, Maryland, Michigan, Nebraska
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Arizona, District of Columbia, Florida, Indiana, Maryland, Massachusetts, Minnesota, New York
2019-11-04
Active, closed
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769B-Cell Acute Lymphoblastic Leukemia
DrugTisagenlecleucel
Novartis Pharmaceuticals
Phase 2
121
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2019-06-24
Active, closed
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03827798Hidradenitis Suppurativa
DrugsArumakimig·Ianalumab·Remibrutinib
Novartis Pharmaceuticals
Phase 2
248
Florida, Georgia, Illinois, Indiana, Pennsylvania, South Carolina
2019-02-27
Recruiting
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157Spinal Muscular Atrophy (SMA)
DrugZolgensma
Novartis Pharmaceuticals
Observational
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Iowa
2018-09-25
Rows per page Showing 1–31 of 31
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/indiana

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 31 of those studies with a site in Indiana that also match the filters currently applied.

How many clinical trials are recruiting in Indiana?

11 of the 31 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Indiana), 31 studies
PhaseStudiesRecruitingShare
Phase 315448.4%
Phase 29229%
Phase 44212.9%
Observational113.2%
Phase 1/2113.2%
Phase 2/3113.2%

Most active sponsors

Lead sponsors with the most studies (Indiana)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3111
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.